Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
America's appallingly high rate of obesity and resultant diabetes cannot do anything but make this company a winner.
Trueheart
I'm an investor in DexCom (DXCM) and just found this on the CNBC crawl.
I will investigate the company.
Trueheart
$TNDM | #Tandem Bullish on Break Above $100
Alert set for break above $100
Indicators bullish .
$105 First target with confluence of
Fibonacci expansion and extension level.
Strong historical weekly resistance level also.
$116 second target to dead cat bounce Fibonacci .382 level.
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.
$TNDM Tandem Diabetes On Breakout Watch
Alert set for break above $93.00,
Indicators bullish .
$100 first target as key psychological resistance .
$105 second target with confluence of
Fibonacci expansion and extension level.
Strong historical weekly resistance level also.
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.
Does anyone know why this is trading?
$TNDM bulls and bears Tandem Diabetes Care Inc Nasdaq Tndm Short Squeeze
News: $TNDM Tandem Diabetes Care Announces FDA Clearance of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology
Automated Insulin Dosing Software First to Receive New Classification by FDA Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of the t:slim X2™ insulin pump ...
Read the whole news TNDM - Tandem Diabetes Care Announces FDA Clearance of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology
News: $TNDM 3 Top Growth Stocks to Buy in the Final Month of Summer
This summer was one of the hottest on record. In fact, July was the hottest month globally since record keeping began 140 years ago. But don't let your melted ice cream derail your quest for wealth. There are still growth stocks out there torching expectations and delivering above-average retu...
Find out more 3 Top Growth Stocks to Buy in the Final Month of Summer
Tandem Diabetes Care Inc Has Huge growth potential
Jim Cramer spoke with Kim Blickenstaff, executive chairman at Tandem Diabetes Care ( TNDM ) , which posted strong earnings last week but quickly reversed, Blickenstaff blamed the sudden reversal in their shares on global uncertainty. He said Tandem has no business in China and is in "acceleration mode."
Currently, only 30% of Type 1 diabetes patients are using a pump, Blickenstaff said, leaving a lot of room for growth for Tandem. The market potential is even greater worldwide, especially in Europe as the condition continues to become a epidemic.
The chart remains bullish but maybe more confirmation required before placing a trade.
Per TNDM 8-k dated 6-09-2019:
Tandem Diabetes Care, Inc. issued a press release announcing results from two studies of the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed loop technology. Details from the two studies, which included data from Protocol 3 of the National Institutes of Health (NIH)-funded International Diabetes Closed Loop trial (DCLP3), and interim data from the Freelife Kid AP study, were presented on June 9, 2019 at the 79th Scientific Sessions of the American Diabetes Association.
PODD technology in combination with TNDM pump for young T1-D, said to delay development of T1-D. Very early in clinical trial.
**************************
"Pediatric Scientific Data for the Omnipod Horizon System Presented at the American Diabetes Association’s 79th Scientific Sessions
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that positive results from the most recent clinical trial of the Omnipod® Horizon™ Automated Insulin Delivery System (Omnipod Horizon System) were presented during the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, California. The study demonstrated that the investigational Omnipod Horizon System performed well and was safe for up to four days of use in children as young as two years old with type 1 diabetes.1
The study was conducted in a supervised hotel setting under free-living conditions with unrestricted meals and daily exercise and included pediatric participants between two and six years old. The study was preceded by seven days of their usual therapy at home with continuous glucose monitoring. Study participants spent significantly less time in hyperglycemia (=250 mg/dL), spent significantly more time in the target glucose range (70-180 mg/dL), and had better overnight glycemic control compared to their usual therapy, which is in line with the positive performance observed in earlier studies including older pediatric, adolescent and adult study participants. During the study, glucose control was maintained in the target range for 73% of the time overall and 85% of the time during the overnight period. The percentage of time spent in the hypoglycemic range (<70 mg/dL) was very low, at 2.9% overall and 2.0% overnight. The investigational Omnipod Horizon System includes unique features that allow diabetes management to be customized by adjusting the target blood glucose levels and insulin delivery....[more]
Another Diabetes Drug Exploding on News: LXRX get in now will still cheap Analyst Price Target @ $34.00 BOOM $$$
Net loss 22 millions , book value $2 , market cap 4 billions , something doesn't add up , oh well
Exploding Back to 70.00's Next week, Go Full Blast Buying now or cry!!! $$$$$ BOOM
Going Green Today!!! Nice Catch from 51.50 Used to trade this stock from 3.00 Holy Karamba!! LOL
WOW! ALL IN @ 51.50 BOOM Lets Going back to 74.00 Very Soon!!! $$$$$
Tandem Diabetes Care Inc $TNDM Retreats, Watch This Trade Level
Tandem Diabetes Care Inc (NASDAQ:TNDM), is a leading manufacturer and developer of medical devices for people with insulin dependent diabetes using its micro-delivery technology. The stock has been pulling back since March 22, 2019 when it traded as high $74.77 a share. Since that recent pivot top, the stock has pulled back and is now trading at $60.33 a share. Traders and investors should note the gap fill window around the $50.00 level on a daily chart. This level should be solid support. There was sideways consolidation around the $50.00 area before the gap higher breakout move in late February 2019 making this a good support level when tested. At this time, the company is scheduled to report earnings on April 25, 2019.
Nick Santiago
InTheMoneyStocks
Tandem Diabetes is on a roll
I can't wait for Vdex Diabetes of Ohio Akron to open.
Vdex Diabetes of Ohio Akron
added 1,200 share short today
Net loss for a year 2018 is 122 millions $ , market cap over 3 billions , something doesn't add up , imo
Agreed. Also insiders dumping like crazy most barely even have a position in the company now lol
Revenues 46 millions , net loss 34 millions , market cap 2,4 billions !!!
Something doesn't add up
What's up with the 15% drop today?? Not seeing anything in the news that would trigger this.
May be shelf placement @ closing bell. I took my profits. Very common after all the recent upgrades.
I’m up $30 a share on this bad boy. Loving the action here.
Agree! > TNDM is a great $$$$$ opportunity.
Bank of America has $45. PT. Several other recent upgrades .
TNDM strong, surpassing targets!
Bought this at $10. First post here on this board since I have been back on Ihub. This is a true gamer. I think we go much higher in the future. $50 plus
Great stock to invest in. The average stock price, volume and product growth are all helping with the bullish trend. Leading indicators predicted a long term trend at the beginning of April for the TNDM stock. #BluSignals
https://www.blusignalsystems.com/why-tndm-stock-surged-leading-indicator-predictions/
This thing is like the energizer bunny.. just an epic run
Huge news for TNDM and DXCM.... this should drive t:slim pump adoption. Continuous Glucose Monitoring dramatically getting improved and should see upside for a long time to come as people using insulin injection convert to pumps, and people on pumps with sensors or finger sticks for calibration get better accuracy as industry gets closer to closed loop systems.
https://www.businesswire.com/news/home/20180621006260/en/Tandem-Diabetes-Care-Announces-FDA-Approval-
Only four major stand-alone Diabetes device companies left; TNMD, DXCM, PODD and MDT. Also ABT.
Oppenheimer analyst Steven Lichtman maintained a Buy rating on Tandem Diabetes (NASDAQ: TNDM) today and set a price target of $24. The company’s shares closed yesterday at $20.31, close to its 52-week high of $21.50.
http://www.analystratings.com/articles/oppenheimer-sticks-to-its-buy-rating-for-tandem-diabetes/
Update on TNDM below...... not mentioned in the article is that I think TNDM is due a decision on Canada distribution by May 6 at the latest. Could be another catalyst coming up shortly here.
https://seekingalpha.com/article/4164371-pivotal-point-tandem-diabetes-care
Really? After 200% gains?!? Expect it to settle, first day it´s losing some steam. Good to see it rise steadily day by day during the last weeks, setback gonna be healthy right now.
Still rocking AH. Never saw a weakness in this one to short. Good Luck.
I'm a long only guy, but I would think there are much better companies out there to short than this one right now. TNDM just released good preliminary numbers, has a couple catalysts on horizon, and seems to be gaining visibility as evidenced by increasing volume the last two months. Yes, it is overbought right now by just about every measure, but that doesn't mean it can't go higher, or it gets another big pop with an announcement of some kind. JMO of course. GL.
Wowza major reversal finally in place here
* * $TNDM Video Chart 03-27-18 * *
Link to Video - click here to watch the technical chart video
* * $TNDM Video Chart 03-02-18 * *
Link to Video - click here to watch the technical chart video
Scandinavia and Canada now. Two areas to enlarge commercial sales. Hope it will give a positive result finally
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
282
|
Created
|
11/26/13
|
Type
|
Free
|
Moderators |
Tandem Diabetes Care, Inc. is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells a family of insulin pump products, which includes the t:slim X2™ Insulin Pump, the next-generation color touchscreen pump, the t:flex® Insulin Pump, the first pump designed for people with greater insulin requirements, and the t:slim G4™ Insulin Pump, the first CGM-enabled pump with touch-screen simplicity. Tandem is based in San Diego, California.
We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Tandem Diabetes Care's financial performance into perspective
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |